EMA Authorised: Ervebo (recombinant vesicular stomatitis virus (strain indiana) with a deletion of the envelope glycoprotein, replaced with the zaire ebolavirus (strain kikwit 1995) surface glycoprotein) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The European Medicines Agency authorised Ervebo for vaccination against Ebola virus disease, using a recombinant vesicular stomatitis virus vector expressing Za…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• Ervebo (rVSVΔG-ZEBOV-GP)

Snippet

Status: Authorised. Therapeutic area: Hemorrhagic Fever, Ebola. MAH: Merck Sharp & Dohme B.V.. Decision date: 27/11/2025